The notices it replaced
- Reissues: PAR-17-032 Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease (R01)
Replaced by PAR-25-374.
Who won it before
44 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $38,287,268 in first-year total cost, median $793,231.
Most frequent study sections
- Special Emphasis Panel[ZAG1 ZIJ-6 (J2)]5
- Special Emphasis Panel[ZAG1 ZIJ-6 (J4)]5
- Special Emphasis Panel[ZAG1 ZIJ-6 (M3)]4
- Special Emphasis Panel[ZAG1 ZIJ-6 (O3)]4
- Special Emphasis Panel[ZAG1 ZIJ-6 (M2)]3
Most frequent institutions
- MASSACHUSETTS GENERAL HOSPITAL4
- HUNTER COLLEGE3
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH3
- BOSTON UNIVERSITY MEDICAL CAMPUS2
- CLEVELAND CLINIC LERNER COM-CWRU2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Systematically screening and validating drug repurposing candidates for Alzheimer's Disease and Related Dementias1R56AG084550-01 | FENG, QIPINGWEI, WEI-QI | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $874,542 | ZAG1 |
| 2024 | Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimers Disease1R01AG084531-01 | LEMERE, CYNTHIA A | BRIGHAM AND WOMEN'S HOSPITAL, MA | $859,410 | ZAG1 |
| 2023 | Harnessing Diverse Bioinformatic Approaches To Repurpose Drugs For Alzheimers Disease And Related Dementias2R01AG058063-06 | ALBERS, MARK WSORGER, PETER KARL | MASSACHUSETTS GENERAL HOSPITAL, MA | $1,054,706 | ZAG1 |
| 2023 | AI-Powered Quantitative Systems Pharmacology for AD Drug Repurposing2R01AG057555-06 | XIE, LEI | HUNTER COLLEGE, NY | $693,857 | ZAG1 |
| 2023 | Drugs repositioning to target TREM2 in Alzheimer disease1R01AG081228-01 | SONG, YUHUA | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $611,134 | ZAG1 |
| 2022 | Develop AD Connectivity Maps with Human iPSC-Derived Brain Cells and their Use1R01AG078164-01 | HUANG, YADONG | J. DAVID GLADSTONE INSTITUTES, CA | $941,764 | ZAG1 |
| 2022 | TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimers Disease1R01AG076448-01 | CHENG, FEIXIONGGAN, LIWANG, FEI | CLEVELAND CLINIC LERNER COM-CWRU, OH | $831,528 | ZAG1 |
| 2022 | Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical Knowledge1R01AG076234-01 | BIAN, JIANGWANG, FEI | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $807,473 | ZAG1 |
| 2022 | Detecting synergistic effects of pharmacological and non-pharmacological interventions for AD/ADRD1R01AG078154-01 | XU, HUAZHANG, RUI | UNIVERSITY OF MINNESOTA, MN | $781,522 | ZAG1 |
| 2022 | MWAS+ – A Novel Drug Repurposing Strategy for ADRD Prevention1R01AG073474-01A1 | AHMED, ALIZAMRINI, EDWARD YZENG, QING | GEORGE WASHINGTON UNIVERSITY, DC | $764,056 | ZAG1 |
| 2022 | The hippocampal dentate gyrus in aging and Alzheimer's disease: boosting transcription of retinoic acid-sensitive genes through vitamin A supplementation and HDAC inhibition1R01AG073826-01A1 | LAWRENCE, JOHN JOSHUA | TEXAS TECH UNIVERSITY HEALTH SCIS CENTER, TX | $636,809 | ZAG1 |
| 2022 | SmartAD for Intelligent Alzheimer’s Disease(AD) Personalized Combination Therapy1R56AG074951-01A1 | XIE, XIANG-QUNXUE, YING | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $395,417 | ZAG1 |
| 2021 | Repurposing drugs for Alzheimer´s disease using a reverse translational approach1RF1AG067996-01A1 | HAGG, SARA | KAROLINSKA INSTITUTE | $1,562,430 | ZAG1 |
| 2021 | Drug repositioning for Alzheimer's disease via genetics, electronic health records, and human iPSC models1R01AG069900-01 · under PAR-17-032 | LI, BINGSHANWEI, WEI-QIWEN, ZHEXING | VANDERBILT UNIVERSITY, TN | $838,304 | ZAG1 |
| 2021 | Translational big data analytic approaches to advance drug repurposing for Alzheimer's disease1R01AG071470-01 | KIM, DOKYOONNING, XIASHEN, LI | UNIVERSITY OF PENNSYLVANIA, PA | $809,200 | ZAG1 |
| 2021 | Systematic modeling and prediction of cell-type-specific and spatiotemporal crosstalk pathways in Alzheimer's Disease1R01AG071496-01 | KIM, DOO YEONWONG, STEPHEN TC | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $806,177 | ZAG1 |
| 2021 | Advancing Drug Repositioning for Alzheimer’s Disease using Real-world Data1R56AG069880-01 · under PAR-17-032 | BIAN, JIANGCHEN, YONGWU, YONGHUIXU, HUA | UNIVERSITY OF FLORIDA, FL | $798,718 | ZAG1 |
| 2021 | CICADA: clinical informatics and computational approaches for drug-repositioning of AD/ADRD1R56AG074604-01 | CHEN, YONGTAO, CUI | UNIVERSITY OF PENNSYLVANIA, PA | $793,964 | ZAG1 |
| 2021 | Advancing drug repositioning and development for Alzheimer's Disease using functional genomics and computational phenomics1R56AG068026-01A1 | GAMAZON, ERIC R | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $755,981 | ZAG1 |
| 2021 | TargetAD: A systems multi-omics approach to drug repositioning in Alzheimer's disease1R01AG069901-01A1 | ARNOLD, MATTHIASKRUMSIEK, JAN | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $624,944 | ZAG1 |
| 2020 | Compound repositioning for Alzheimer's Disease using knowledge graphs, insurance claims data, and gene expression complementarity1R01AG066750-01 · under PAR-17-032 | SU, ANDREW I | SCRIPPS RESEARCH INSTITUTE, THE, CA | $885,874 | ZAG1 |
| 2020 | Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's Disease1R01AG068030-01 · under PAR-17-032 | BRENNAND, KRISTEN JENNIFERCAI, DONGMINGZHANG, BIN | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $845,873 | ZAG1 |
| 2020 | Finding combinatorial drug repositioning therapy for Alzheimer's disease and related dementias1R01AG066749-01 · under PAR-17-032 | JIANG, XIAOQIANZHENG, WENJIN JIM | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $781,522 | ZAG1 |
| 2020 | Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for Alzheimers Disease1R01AG066707-01 · under PAR-17-032 | CHENG, FEIXIONG | CLEVELAND CLINIC LERNER COM-CWRU, OH | $634,650 | ZAG1 |
| 2020 | Combine Genomics and Symptoms Data Driven Models to Discover Synergistic Combinatory Therapies for Alzheimer's Disease1R56AG065352-01A1 · under PAR-17-032 | LI, FUHAI | WASHINGTON UNIVERSITY, MO | $500,322 | ZAG1 |
| 2019 | Big data and small molecules for Alzheimer's disease1RF1AG063913-01 · under PAR-17-032 | GOLDSTEIN, LEE E.XIA, WEIMING | BOSTON UNIVERSITY MEDICAL CAMPUS, MA | $2,035,223 | NIA |
| 2019 | Predictive Networks-based in-silico approach for Precision Medicine-repurposing for Alzheimer's Disease1R56AG062620-01 · under PAR-17-032 | BRADSHAW, ELIZABETH MCHANG, RUIKANEKIYO, TAKAHISA | UNIVERSITY OF ARIZONA, AZ | $836,812 | ZAG1 |
| 2019 | The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.1R01AG062547-01 · under PAR-17-032 | HIDE, WINSTON ALEXANDERKIM, DOO YEONTANZI, RUDOLPH EMILE | MASSACHUSETTS GENERAL HOSPITAL, MA | $686,190 | ZAG1 |
| 2019 | Personalized Combination Therapy for AD with Common Comorbidities1R56AG062493-01 · under PAR-17-032 | WANG, LIRONGXIE, XIANG-QUN | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $377,443 | ZAG1 |
| 2018 | SYSTEMATIC DRUG REPURPOSING TARGETING IMMUNE ACTIVATION NETWORKS IN ALZHEIMER'S DISEASE (AD)1RF1AG059319-01 · under PAR-17-032 | EHRLICH, MICHELLE EGANDY, SAMUEL E. | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $4,186,456 | ZAG1 |
| 2018 | Harnessing Diverse BioInformatic Approaches to Repurpose Drugs for Alzheimers Disease1R01AG058063-01A1 · under PAR-17-032 | ALBERS, MARK W | MASSACHUSETTS GENERAL HOSPITAL, MA | $828,046 | ZAG1 |
| 2018 | Quantitative systems pharmacology and translational study of pramlintide for Alzheimer's disease1R56AG059805-01 · under PAR-17-032 | QIU, WEI QIAO WENDY | BOSTON UNIVERSITY MEDICAL CAMPUS, MA | $810,558 | ZAG1 |
| 2018 | Drug repurposing for Alzheimer's disease using both observational and chemical genomics data1R56AG059428-01 · under PAR-17-032 | TROPSHA, ALEXANDER | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $794,078 | ZAG1 |
| 2018 | A knowledge map to find Alzheimer's disease drugs1R01AG061105-01 · under PAR-17-032 | LICHTARGE, OLIVIER | BAYLOR COLLEGE OF MEDICINE, TX | $792,498 | ZAG1 |
| 2018 | Phenotypic screening and computational modeling for development of combination therapies for Alzheimer's disease1R56AG059612-01 · under PAR-17-032 | LEZON, TIMOTHY RSCHURDAK, MARK E | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $782,279 | ZAG1 |
| 2018 | Drug repurposing for Alzheimer's disease using structural systems pharmacology.1R01AG057555-01A1 · under PAR-17-032 | XIE, LEI | HUNTER COLLEGE, NY | $779,392 | ZAG1 |
| 2018 | Leveraging the Human Non-Coding Transcriptome to Identify Therapeutics for Healthy Aging and Alzheimers Disease1R56AG061911-01 · under PAR-17-032 | VOLMAR, CLAUDE-HENRYWAHLESTEDT, CLAES ROBERT | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $749,747 | ZAG1 |
| 2018 | Systematic Alzheimer's disease drug repositioning (SMART) based on bioinformatics-guided phenotype screening and image-omics1R01AG057635-01A1 · under PAR-17-032 | WONG, STEPHEN TC | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $694,058 | ZAG1 |
| 2018 | Omic analyses for stratifying Alzheimer's subtypes and identifying novel drug targets1R56AG061163-01 · under PAR-17-032 | CHEN, CHI-HUA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $560,128 | ZAG1 |
| 2018 | A Translational Bioinformatics Approach to Rescuing Synaptic and Neurophysiologic Dysfunction in Alzheimer's Disease1R01AG059854-01 · under PAR-17-032 | TEICH, ANDREW FRANKLIN | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $460,731 | ZAG1 |
| 2017 | ApoE Genotype-Directed Drug Repositioning and Combination Therapy for Alzheimer's Disease1R01AG057683-01 · under PAR-17-032 | HUANG, YADONGSIROTA, MARINA | J. DAVID GLADSTONE INSTITUTES, CA | $875,721 | ZAG1 |
| 2017 | Harnessing Diverse BioInformatic Approaches to Repurpose Drugs for Alzheimer's Disease1R56AG058063-01 · under PAR-17-032 | ALBERS, MARK WSORGER, PETER KARL | MASSACHUSETTS GENERAL HOSPITAL, MA | $835,424 | ZAG1 |
| 2017 | Drug repurposing for Alzheimer's disease using structural systems pharmacology1R56AG057555-01 · under PAR-17-032 | XIE, LEI | HUNTER COLLEGE, NY | $770,770 | ZAG1 |
| 2017 | An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's Disease1R01AG057557-01 · under PAR-17-032 | XU, RONGYAN, RIQIANG | CASE WESTERN RESERVE UNIVERSITY, OH | $541,537 | ZAG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.